Share Price and Basic Stock Data
Last Updated: February 9, 2026, 9:48 pm
| PEG Ratio | -2.16 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Amerise Biosciences Ltd operates in the pharmaceuticals sector, with its current market capitalization reported at ₹4.36 Cr and a share price of ₹0.66. The company has struggled with revenue generation, recording zero sales from December 2022 through September 2023. However, a slight improvement is observed in the subsequent quarters, with sales rising to ₹0.04 Cr in March 2024, eventually reaching ₹0.19 Cr by March 2025. The trailing twelve months (TTM) revenue stood at ₹0.32 Cr. This shows a potential recovery trajectory, albeit from a very low base. Comparatively, the industry often sees higher sales figures, indicating that Amerise has significant ground to cover to align with sector norms. The lack of revenue generation in the preceding periods raises questions about product pipeline efficacy and market penetration strategies.
Profitability and Efficiency Metrics
Profitability remains a significant concern for Amerise Biosciences, with a reported net profit of just ₹0.04 Cr in the latest fiscal year, up from losses in previous periods, including a net loss of ₹0.12 Cr in March 2023. The operating profit margin (OPM) fluctuated, with a notable 50% recorded in March 2024, but dropped to 25% by December 2025, indicating volatility in operational efficiency. The company’s return on equity (ROE) stands at 0.19%, which is notably low compared to typical sector averages, suggesting that shareholder returns are minimal. The interest coverage ratio (ICR) is strong at 39.00x, indicating that the company can comfortably cover its interest obligations, but the overall profitability metrics reflect an ongoing struggle to achieve consistent earnings.
Balance Sheet Strength and Financial Ratios
The balance sheet of Amerise Biosciences reveals a precarious financial position, with total liabilities reported at ₹8.46 Cr against total assets of ₹8.46 Cr. Reserves are negative at ₹-1.28 Cr, indicating a cumulative loss situation that can potentially deter future investments. The company has reported no borrowings, which is a strength, reflecting a debt-free status. However, the current ratio is alarmingly low at 0.01, suggesting significant liquidity issues and potential challenges in meeting short-term obligations. The price-to-book value (P/BV) ratio is at 1.12x, indicating that the stock is trading at a premium to its book value, which may not be justified given the company’s financial struggles. These factors collectively indicate a need for strategic financial restructuring to bolster balance sheet strength.
Shareholding Pattern and Investor Confidence
Amerise Biosciences has a public shareholding of 100%, with 35,676 shareholders reported as of September 2025. This indicates a broad base of retail investors, reflecting a level of investor confidence despite the company’s financial challenges. The increase in the number of shareholders from 18,842 in December 2022 to 35,676 in September 2025 demonstrates growing interest, possibly due to the recent positive developments in sales. However, the absence of institutional investment (FIIs and DIIs) could suggest a lack of confidence from larger investors, which may hinder the company’s future growth prospects. A more diverse shareholder structure might be necessary to instill greater investor confidence and support for capital raising efforts in the future.
Outlook, Risks, and Final Insight
The outlook for Amerise Biosciences hinges on its ability to convert recent revenue increases into sustainable growth while addressing its profitability and liquidity challenges. Key strengths include a debt-free status and a solid interest coverage ratio, positioning the company favorably in terms of financial stability. However, significant risks are posed by its negative reserves and low current ratio, which indicate potential operational and financial distress. Additionally, the volatility in profitability metrics raises concerns about long-term viability. Strategically, the company must focus on enhancing its product pipeline and operational efficiency to meet market expectations. A successful turnaround could attract institutional investment, bolstering its capital base and enabling more aggressive growth strategies.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 127 Cr. | 101 | 185/84.3 | 28.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,651 Cr. | 336 | 479/192 | 76.4 | 24.3 | 0.20 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 31.4 Cr. | 42.4 | 82.0/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 79.1 Cr. | 54.0 | 54.0/17.0 | 188 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,092.40 Cr | 1,113.02 | 54.45 | 201.93 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 | 0.19 | 0.06 | 0.07 | 0.04 |
| Expenses | 0.05 | 0.02 | 0.07 | 0.04 | 0.06 | 0.02 | 0.05 | 0.03 | 0.02 | 0.08 | 0.07 | 0.11 | 0.03 |
| Operating Profit | -0.05 | -0.02 | -0.07 | -0.04 | -0.06 | 0.02 | -0.05 | -0.03 | -0.02 | 0.11 | -0.01 | -0.04 | 0.01 |
| OPM % | 50.00% | 57.89% | -16.67% | -57.14% | 25.00% | ||||||||
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.05 | -0.02 | -0.07 | -0.04 | -0.06 | 0.02 | -0.05 | -0.03 | -0.02 | 0.11 | -0.01 | -0.04 | 0.01 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -0.05 | -0.02 | -0.07 | -0.04 | -0.06 | 0.02 | -0.05 | -0.03 | -0.02 | 0.11 | -0.01 | -0.04 | 0.01 |
| EPS in Rs | -0.01 | -0.00 | -0.01 | -0.01 | -0.01 | 0.00 | -0.01 | -0.00 | -0.00 | 0.02 | -0.00 | -0.01 | 0.00 |
Last Updated: February 3, 2026, 6:46 am
Below is a detailed analysis of the quarterly data for Amerise Biosciences Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:
- For Sales, as of Dec 2025, the value is 0.04 Cr.. The value appears to be declining and may need further review. It has decreased from 0.07 Cr. (Sep 2025) to 0.04 Cr., marking a decrease of 0.03 Cr..
- For Expenses, as of Dec 2025, the value is 0.03 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.11 Cr. (Sep 2025) to 0.03 Cr., marking a decrease of 0.08 Cr..
- For Operating Profit, as of Dec 2025, the value is 0.01 Cr.. The value appears strong and on an upward trend. It has increased from -0.04 Cr. (Sep 2025) to 0.01 Cr., marking an increase of 0.05 Cr..
- For OPM %, as of Dec 2025, the value is 25.00%. The value appears strong and on an upward trend. It has increased from -57.14% (Sep 2025) to 25.00%, marking an increase of 82.14%.
- For Other Income, as of Dec 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 0.00 Cr..
- For Interest, as of Dec 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 0.00 Cr..
- For Depreciation, as of Dec 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Dec 2025, the value is 0.01 Cr.. The value appears strong and on an upward trend. It has increased from -0.04 Cr. (Sep 2025) to 0.01 Cr., marking an increase of 0.05 Cr..
- For Tax %, as of Dec 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 0.00%.
- For Net Profit, as of Dec 2025, the value is 0.01 Cr.. The value appears strong and on an upward trend. It has increased from -0.04 Cr. (Sep 2025) to 0.01 Cr., marking an increase of 0.05 Cr..
- For EPS in Rs, as of Dec 2025, the value is 0.00. The value appears strong and on an upward trend. It has increased from -0.01 (Sep 2025) to 0.00, marking an increase of 0.01.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:15 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 1.18 | -0.00 | -0.00 | 9.58 | 0.01 | 0.04 | 0.19 | 0.32 |
| Expenses | 0.03 | 0.05 | 0.03 | 0.94 | 0.02 | 1.18 | 0.15 | 0.17 | 9.03 | 0.13 | 0.19 | 0.18 | 0.28 |
| Operating Profit | -0.03 | -0.05 | -0.03 | -0.94 | -0.02 | -0.00 | -0.15 | -0.17 | 0.55 | -0.12 | -0.15 | 0.01 | 0.04 |
| OPM % | -0.00% | 5.74% | -1,200.00% | -375.00% | 5.26% | 12.50% | |||||||
| Other Income | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.17 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 |
| Interest | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 |
| Depreciation | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 |
| Profit before tax | -0.03 | -0.05 | -0.03 | -0.94 | -0.02 | -0.00 | -0.15 | -0.34 | 0.55 | -0.12 | -0.15 | 0.01 | 0.04 |
| Tax % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | ||
| Net Profit | -0.03 | -0.05 | -0.03 | -0.94 | -0.02 | -0.00 | -0.15 | -0.34 | 0.55 | -0.12 | -0.15 | 0.01 | 0.04 |
| EPS in Rs | -0.00 | -0.01 | -0.00 | -0.14 | -0.00 | -0.00 | -0.02 | -0.05 | 0.08 | -0.02 | -0.02 | 0.00 | 0.01 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -66.67% | 40.00% | -3033.33% | 97.87% | 100.00% | -126.67% | 261.76% | -121.82% | -25.00% | 106.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | 106.67% | -3073.33% | 3131.21% | 2.13% | -226.67% | 388.43% | -383.58% | 96.82% | 131.67% |
Amerise Biosciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -73% |
| TTM: | 525% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 16% |
| 3 Years: | -74% |
| TTM: | 138% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -18% |
| 5 Years: | -3% |
| 3 Years: | -10% |
| 1 Year: | -13% |
| Return on Equity | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | 0% |
| 3 Years: | -2% |
| Last Year: | 0% |
Last Updated: September 5, 2025, 2:16 pm
Balance Sheet
Last Updated: February 1, 2026, 4:17 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 |
| Reserves | 0.00 | -0.05 | -0.07 | -1.01 | -1.03 | -1.03 | -1.18 | -1.52 | -0.97 | -1.09 | -1.23 | -1.23 | -1.28 |
| Borrowings | 0.59 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.09 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.04 | 0.01 | 0.02 | 0.60 | 0.54 | 6.27 | 0.04 | 0.01 | 3.08 | 3.06 |
| Total Liabilities | 7.20 | 6.56 | 6.54 | 5.64 | 5.59 | 5.60 | 6.03 | 5.63 | 11.99 | 5.65 | 5.39 | 8.46 | 8.39 |
| Fixed Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 5.14 | 4.82 | 5.89 | 2.34 | 2.31 | 0.54 | 5.37 | 3.04 | 4.69 | 4.57 | 2.27 | 2.38 | 3.77 |
| Other Assets | 2.06 | 1.74 | 0.65 | 3.30 | 3.28 | 5.06 | 0.66 | 2.59 | 7.30 | 1.08 | 3.12 | 6.08 | 4.62 |
| Total Assets | 7.20 | 6.56 | 6.54 | 5.64 | 5.59 | 5.60 | 6.03 | 5.63 | 11.99 | 5.65 | 5.39 | 8.46 | 8.39 |
Below is a detailed analysis of the balance sheet data for Amerise Biosciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 6.61 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 6.61 Cr..
- For Reserves, as of Sep 2025, the value is -1.28 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -1.23 Cr. (Mar 2025) to -1.28 Cr., marking a decline of 0.05 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. However, Reserves are negative, which is a major warning sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 3.06 Cr.. The value appears to be improving (decreasing). It has decreased from 3.08 Cr. (Mar 2025) to 3.06 Cr., marking a decrease of 0.02 Cr..
- For Total Liabilities, as of Sep 2025, the value is 8.39 Cr.. The value appears to be improving (decreasing). It has decreased from 8.46 Cr. (Mar 2025) to 8.39 Cr., marking a decrease of 0.07 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 3.77 Cr.. The value appears strong and on an upward trend. It has increased from 2.38 Cr. (Mar 2025) to 3.77 Cr., marking an increase of 1.39 Cr..
- For Other Assets, as of Sep 2025, the value is 4.62 Cr.. The value appears to be declining and may need further review. It has decreased from 6.08 Cr. (Mar 2025) to 4.62 Cr., marking a decrease of 1.46 Cr..
- For Total Assets, as of Sep 2025, the value is 8.39 Cr.. The value appears to be declining and may need further review. It has decreased from 8.46 Cr. (Mar 2025) to 8.39 Cr., marking a decrease of 0.07 Cr..
However, the Borrowings (0.00 Cr.) are higher than the Reserves (-1.28 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.62 | -0.05 | -0.03 | -0.94 | -0.02 | 0.00 | -0.15 | -0.17 | 0.47 | -0.21 | -0.15 | 0.01 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 1,382.67 | 236.98 | 0.00 | 0.00 | 0.00 | |||||||
| Inventory Days | 0.00 | 0.00 | ||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 1,382.67 | 236.98 | 0.00 | 0.00 | 0.00 | |||||||
| Working Capital Days | 1,376.48 | -1.91 | -1,460.00 | -182.50 | -5,897.63 | |||||||
| ROCE % | -0.36% | -0.73% | -0.46% | -15.49% | -0.36% | 0.00% | -2.72% | -6.46% | 10.18% | -2.12% | -2.73% | 0.19% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 0.00 | -0.02 | -0.02 | 0.08 | -0.05 |
| Diluted EPS (Rs.) | 0.00 | -0.02 | -0.02 | 0.08 | -0.05 |
| Cash EPS (Rs.) | 0.00 | -0.02 | -0.01 | 0.08 | -0.05 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 0.81 | 0.81 | 0.83 | 0.85 | 0.77 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 0.81 | 0.81 | 0.83 | 0.85 | 0.77 |
| Revenue From Operations / Share (Rs.) | 0.00 | 0.00 | 0.00 | 1.36 | 0.00 |
| PBDIT / Share (Rs.) | 0.00 | -0.02 | -0.01 | 0.08 | -0.05 |
| PBIT / Share (Rs.) | 0.00 | -0.02 | -0.01 | 0.08 | -0.05 |
| PBT / Share (Rs.) | 0.00 | -0.02 | -0.01 | 0.08 | -0.05 |
| Net Profit / Share (Rs.) | 0.00 | -0.02 | -0.01 | 0.08 | -0.05 |
| PBDIT Margin (%) | 0.00 | 0.00 | 0.00 | 6.09 | 0.00 |
| PBIT Margin (%) | 0.00 | 0.00 | 0.00 | 6.09 | 0.00 |
| PBT Margin (%) | 0.00 | 0.00 | 0.00 | 6.09 | 0.00 |
| Net Profit Margin (%) | 0.00 | 0.00 | 0.00 | 6.09 | 0.00 |
| Return on Networth / Equity (%) | 0.10 | -2.71 | -2.15 | 9.73 | -6.62 |
| Return on Capital Employeed (%) | 0.14 | -2.71 | -2.11 | 9.59 | -6.62 |
| Return On Assets (%) | 0.06 | -2.71 | -2.10 | 4.58 | -5.99 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Asset Turnover Ratio (%) | 0.00 | 0.00 | 0.00 | 1.02 | 0.00 |
| Current Ratio (X) | 0.01 | 1.48 | 0.36 | 0.99 | 0.03 |
| Quick Ratio (X) | 0.01 | 1.48 | 0.36 | 0.99 | 0.03 |
| Interest Coverage Ratio (X) | 39.00 | -486.00 | -1188.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (Post Tax) (X) | 29.50 | -486.00 | -1188.00 | 0.00 | 0.00 |
| Enterprise Value (Cr.) | 5.99 | 4.34 | 4.70 | 9.06 | 10.88 |
| EV / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 1.01 | 0.00 |
| EV / EBITDA (X) | 767.96 | -29.76 | -39.57 | 16.49 | -32.28 |
| MarketCap / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 0.99 | 0.00 |
| Price / BV (X) | 1.12 | 0.81 | 0.83 | 1.59 | 2.14 |
| Price / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 0.99 | 0.00 |
| EarningsYield | 0.00 | -0.03 | -0.02 | 0.06 | -0.03 |
After reviewing the key financial ratios for Amerise Biosciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has increased from -0.02 (Mar 24) to 0.00, marking an increase of 0.02.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has increased from -0.02 (Mar 24) to 0.00, marking an increase of 0.02.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. It has increased from -0.02 (Mar 24) to 0.00, marking an increase of 0.02.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.81. There is no change compared to the previous period (Mar 24) which recorded 0.81.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.81. There is no change compared to the previous period (Mar 24) which recorded 0.81.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 2. It has increased from -0.02 (Mar 24) to 0.00, marking an increase of 0.02.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.00. This value is within the healthy range. It has increased from -0.02 (Mar 24) to 0.00, marking an increase of 0.02.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.00. This value is within the healthy range. It has increased from -0.02 (Mar 24) to 0.00, marking an increase of 0.02.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 2. It has increased from -0.02 (Mar 24) to 0.00, marking an increase of 0.02.
- For PBDIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Net Profit Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 15. It has increased from -2.71 (Mar 24) to 0.10, marking an increase of 2.81.
- For Return on Capital Employeed (%), as of Mar 25, the value is 0.14. This value is below the healthy minimum of 10. It has increased from -2.71 (Mar 24) to 0.14, marking an increase of 2.85.
- For Return On Assets (%), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has increased from -2.71 (Mar 24) to 0.06, marking an increase of 2.77.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Current Ratio (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 1.5. It has decreased from 1.48 (Mar 24) to 0.01, marking a decrease of 1.47.
- For Quick Ratio (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 1. It has decreased from 1.48 (Mar 24) to 0.01, marking a decrease of 1.47.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 39.00. This value is within the healthy range. It has increased from -486.00 (Mar 24) to 39.00, marking an increase of 525.00.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 29.50. This value is within the healthy range. It has increased from -486.00 (Mar 24) to 29.50, marking an increase of 515.50.
- For Enterprise Value (Cr.), as of Mar 25, the value is 5.99. It has increased from 4.34 (Mar 24) to 5.99, marking an increase of 1.65.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EV / EBITDA (X), as of Mar 25, the value is 767.96. This value exceeds the healthy maximum of 15. It has increased from -29.76 (Mar 24) to 767.96, marking an increase of 797.72.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 1.12. This value is within the healthy range. It has increased from 0.81 (Mar 24) to 1.12, marking an increase of 0.31.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has increased from -0.03 (Mar 24) to 0.00, marking an increase of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Amerise Biosciences Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 0.14% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.1% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 29.5
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.01
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 73.6 (Industry average Stock P/E: 54.45)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 24, Laxmi Chambers, Ahmedabad Gujarat 380014 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Dineshkumar Rathod | WholeTime Director & CFO |
| Ms. Manisha Patel | Director |
| Mr. Kelash Bunkar | Director |
FAQ
What is the intrinsic value of Amerise Biosciences Ltd?
Amerise Biosciences Ltd's intrinsic value (as of 10 February 2026) is ₹0.06 which is 92.31% lower the current market price of ₹0.78, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹5.15 Cr. market cap, FY2025-2026 high/low of ₹1.06/0.51, reserves of ₹-1.28 Cr, and liabilities of ₹8.39 Cr.
What is the Market Cap of Amerise Biosciences Ltd?
The Market Cap of Amerise Biosciences Ltd is 5.15 Cr..
What is the current Stock Price of Amerise Biosciences Ltd as on 10 February 2026?
The current stock price of Amerise Biosciences Ltd as on 10 February 2026 is ₹0.78.
What is the High / Low of Amerise Biosciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Amerise Biosciences Ltd stocks is ₹1.06/0.51.
What is the Stock P/E of Amerise Biosciences Ltd?
The Stock P/E of Amerise Biosciences Ltd is 73.6.
What is the Book Value of Amerise Biosciences Ltd?
The Book Value of Amerise Biosciences Ltd is 0.81.
What is the Dividend Yield of Amerise Biosciences Ltd?
The Dividend Yield of Amerise Biosciences Ltd is 0.00 %.
What is the ROCE of Amerise Biosciences Ltd?
The ROCE of Amerise Biosciences Ltd is 0.19 %.
What is the ROE of Amerise Biosciences Ltd?
The ROE of Amerise Biosciences Ltd is 0.19 %.
What is the Face Value of Amerise Biosciences Ltd?
The Face Value of Amerise Biosciences Ltd is 1.00.